Literature DB >> 19130007

Stroke and depression: clinical features and treatment.

R Torta1, A Cicolin, R Keller.   

Abstract

CONCLUSION: Cerebrovascular diseases are associated with a high incidence of depressive disorder, but despite this high level of comorbidity, depression appears to go largely unrecognized and untreated. This problem may have serious consequences as depressive disorder worsens the prognosis eitherquoad vitam orquoad valetudinem, increases medical costs, and delays the return to work or to a normal social functioning. If previous treatments with traditional antidepressants such as TCAs were difficult in these patients because of the known cardiovascular and anticholinergic side effects, new antide-pressants (such as SSRIs, noradrenergic and specific serotonine antidepressants (NaSSAs), noradrenergic reuptake inhibitors (NARIs) may offer therapeutic advantages as they have little or no effect on cardiac conduction, only transient or no effect on orthostatic hypotension, and no effect on cognitive performances.

Entities:  

Year:  1998        PMID: 19130007     DOI: 10.1007/BF00713875

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  21 in total

1.  Anger attacks in poststroke depression: response to fluoxetine.

Authors:  E Weinman; P E Ruskin
Journal:  Am J Psychiatry       Date:  1994-12       Impact factor: 18.112

Review 2.  Affective disorders and cerebral vascular disease.

Authors:  S E Starkstein; R G Robinson
Journal:  Br J Psychiatry       Date:  1989-02       Impact factor: 9.319

3.  Major depression in stroke patients. A 3-year longitudinal study.

Authors:  M Aström; R Adolfsson; K Asplund
Journal:  Stroke       Date:  1993-07       Impact factor: 7.914

4.  Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram.

Authors:  G Andersen; K Vestergaard; L Lauritzen
Journal:  Stroke       Date:  1994-06       Impact factor: 7.914

5.  Nortriptyline treatment of post-stroke depression: a double-blind study.

Authors:  J R Lipsey; R G Robinson; G D Pearlson; K Rao; T R Price
Journal:  Lancet       Date:  1984-02-11       Impact factor: 79.321

6.  Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.

Authors:  M Dam; P Tonin; A De Boni; G Pizzolato; S Casson; M Ermani; U Freo; L Piron; L Battistin
Journal:  Stroke       Date:  1996-07       Impact factor: 7.914

7.  Association of depression with 10-year poststroke mortality.

Authors:  P L Morris; R G Robinson; P Andrzejewski; J Samuels; T R Price
Journal:  Am J Psychiatry       Date:  1993-01       Impact factor: 18.112

8.  Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. A controlled clinical study.

Authors:  L Lauritzen; B B Bendsen; T Vilmar; E B Bendsen; M Lunde; P Bech
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

9.  Activation of the central pattern generators for locomotion by serotonin and excitatory amino acids in neonatal rat.

Authors:  J R Cazalets; Y Sqalli-Houssaini; F Clarac
Journal:  J Physiol       Date:  1992-09       Impact factor: 5.182

10.  Risk factors for post-stroke depression.

Authors:  G Andersen; K Vestergaard; M Ingemann-Nielsen; L Lauritzen
Journal:  Acta Psychiatr Scand       Date:  1995-09       Impact factor: 6.392

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.